- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03941626
Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies
February 3, 2021 updated by: Shenzhen BinDeBio Ltd.
EGFRvIII/DR5/NY-ESO-1/Mesothelin CAR-T/TCR-T Cells Immunotherapy for Solid Malignancies
This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The study is a multi-target gene-modified immunotherapy.
CAR-T/TCR-T cells include four different tumor-specific antibody.They are as following:anti-NY-ESO-1 antibody foresophagus cancer;anti-DR5 antibody for hepatoma;;anti-EGFR vIII antibody for hepatoma and glioma;anti-Mesothelin antibody for gastric cancer.
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: ZHONG HUA YANG
- Phone Number: +8618938688105 +8618938688105
- Email: zh.yang@bindebio.com
Study Locations
-
-
Henan
-
Zhengzhou, Henan, China, 450052
- Recruiting
- HeNan Provincial People's Hospital
-
Contact:
- Shuangyin Han
- Phone Number: +8613203710057
- Email: hansyzzu@163.com
-
Contact:
- Chun-Xiao Ma
- Phone Number: +8615038287266
- Email: chxma@126.com
-
Principal Investigator:
- Shuangyin Han
-
Principal Investigator:
- Chun-Xiao Ma
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must be willing to sign an informed consent.
- Male or female patients aged 18 to 70 years .
- Estimated survival of ≥ 12 weeks.
- Pathological sections with positive expression of NY-ESO-1, Mesothelin, EGFRvIII and DR5 was confirmed by biopsy IHC test within 12 months.If NY-ESO-1 is positive expression ,positive HLAA*0201 is required at the same time.
- Solid tumor must have at least one measureable disease according to RECIST 1.1.
- Routine blood test#hemoglobin>=90 g/L; platelet>=50×10^9/L.
- Liver function:ALT and AST≤2.5 times upper limits of normal (If the tumor infiltration is the main cause of abnormal liver function ,ALT and AST≤5 times upper limits of normal); bilirubin<2.0 mg/dL.
- Renal function:BUN: 9-20mg / dl; serum creatinine≤ 1.5 times upper limits of normal; endogenous creatinine clearance rate≥50 ml/min .
- Negative serum antibody for EBV, CMV, HIV , syphilis, HBVa nd HCV.
- Cardiac function: stable hemodynamic and left ventricular ejection fraction (LVEF)>=55%.
- ECOG score:0-1.
- Adequate venous access for apheresis, and no other contraindications for leukapheresis .
- Women of child-bearing age must have evidence of negative pregnancy test. Subjects of reproductive potential must agree to use acceptable birth control methods within 1 year after treatment, as described in protocol.
- Subjects with hypertension/diabetes must be stable blood pressure/blood glucose or ≤CTCAE 1 level 2 weeks before the screening.
In addition to the above criteria for inclusion, the following criteria shall be met according to the indications:
Patients with glioblastoma:
- First disease progression or disease recurrence (≥ 1 cm and ≤ 5 cm) of a supratentorial WHO grade IV malignant glioma (GBM or gliosarcoma) based on imaging studies with measurable disease.
- EGFRvIII, the target antigen, must be identified on tumor tissue by IHC or PCR, i.e. EGFRvIII positive via pathology report.
- Insensitivity to chemoradiotherapy or chemoradiotherapy failure after operation molecular pathology.
- Refused to receive radiotherapy or chemotherapy treatment.
Patients with liver cancer
- DR5 or EGFRvIII positive via pathology report.
- Untreatable by surgery ; Or postoperative recurrence ;Or no effective treatment.
- Liver function:child-pugh A grade or child-pugh B grade.
Patients with gastric cancer
- Mesothelin positive via pathology report.
- The pathological stage:IIIA~IV.
- chemoradiotherapy failure
- Refused or unable to get surgery.
Patients with esophageal cancer
- NY-ESO-1 positive via pathology report and HLA-A*0201 positive in blood.
- Refuse or unable to get surgery.
- Postoperative recurrence or chemoradiotherapy failure.
Exclusion Criteria:
- ECOG≥2.
- malignant tumor cells with T cell origin via pathology test.
- Organ failure: stage III or IV congestive heart failure; Renal failure and uremia; respiratory failure; disturbance of consciousness.
- Acute or chronic GVHD after allogeneic hematopoiesis; Or being treated for GVHD; Or hormone or immunosuppressant used within 30 days
- steroid hormoneswere used before and after blood collection and infusion
- Patients with HIV infection or active hepatitis
- Uncontrolled active infection.
- Enrolled to other clinical study in the last 4 weeks.
- Patients with systemic auto-immune disease or immunodeficiency.
- Patients with neuropathy or psychosis, including dementia or epilepsy, or history of psychotropic substance abuse, or other substantial lesions that may increase central neurotoxicity.
- Concomitant with the second tumor or other malignant tumors.
- Patients with bone metastases are at risk of a pathological fracture resulting in paraplegia or life threatening.
- Live attenuated vaccine was administered within 4 weeks prior to blood collection.
- Blood oxygen saturation is maintained by oxygen inhalation.
- Received major surgery within 2 weeks prior to screening ;Or Plan to receive surgery during study or within 2 weeks after injection.
- Other patients that researchers considered unsuitable for inclusion.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CAR-T/TCR-T cells immunotherapy
Enrolled patients will receive CAR-T cell immunotherapy with several different specific Chimeric antigen receptors aiming at different antigens respectively by infusion.
|
According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events evaluated with NCI CTC AE, version 4.0
Time Frame: 48 months
|
Safety evaluation
|
48 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical response
Time Frame: 48 months
|
Clinical response to T-cell infusion, especially change of tumor volume will be evaluated by comparing disease identified by computed tomography, magnetic resonance imaging.
|
48 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2019
Primary Completion (Anticipated)
May 1, 2021
Study Completion (Anticipated)
December 1, 2021
Study Registration Dates
First Submitted
May 6, 2019
First Submitted That Met QC Criteria
May 6, 2019
First Posted (Actual)
May 8, 2019
Study Record Updates
Last Update Posted (Actual)
February 4, 2021
Last Update Submitted That Met QC Criteria
February 3, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019BDB016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioma
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics; Dragon Master FoundationNot yet recruitingGlioma | Low-grade Glioma | Glioma, Malignant | Low Grade Glioma of Brain | Glioma IntracranialUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); Food and Drug Administration (FDA)Active, not recruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III GliomaUnited States
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics, Inc; Dragon Master FoundationRecruitingGlioma | High Grade Glioma | Glioma, Malignant | Diffuse Glioma | Glioma IntracranialUnited States
-
ChimerixActive, not recruitingGlioblastoma | Diffuse Midline Glioma | H3 K27M Glioma | Thalamic Glioma | Infratentorial Glioma | Basal Ganglia GliomaUnited States
-
University of California, San FranciscoBeiGene USA, Inc.; Pacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | Low Grade Glioma | Recurrent WHO Grade II Glioma | WHO Grade II GliomaUnited States
-
National Cancer Institute (NCI)RecruitingGlioma | High Grade Glioma | Malignant Glioma | Gliomas | Low Grade GliomaUnited States
-
Beijing Tiantan HospitalDuke UniversityUnknownGlioblastoma | High Grade Glioma | Glioma, Malignant | Glioma of BrainstemChina
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGlioblastoma | Malignant Glioma | WHO Grade III Glioma | Recurrent Glioma | Refractory GliomaUnited States
-
Hospital del Río HortegaCompletedGlioma | Glioblastoma | Low-grade Glioma | Glioma, Malignant | High-grade GliomaSpain
-
Sabine Mueller, MD, PhDPacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent Grade III Glioma | Grade III GliomaUnited States, Australia, Israel, Switzerland
Clinical Trials on CAR-T/TCR-T cells immunotherapy
-
The Second Hospital of Nanjing Medical UniversityUnknownNasopharyngeal NeoplasmsChina
-
Fudan UniversityGuangzhou Bioresette Biomedical Technology Co., Ltd.; Chaosu Hu,Principal Investigator...RecruitingNasopharyngeal CarcinomaChina
-
Sun Yat-sen UniversityUnknownNasopharyngeal CarcinomaChina
-
Timmune Biotech Inc.The Second Affiliated Hospital of Hainan Medical University; Hainan Cancer...Unknown
-
Zhongda HospitalRecruitingSafety and Efficacy of TCR-like CAR-TChina
-
Fuda Cancer Hospital, GuangzhouWithdrawnCAR-T Cell Immunotherapy | Glioma of Brain
-
Second Affiliated Hospital of Guangzhou Medical...Tcell Immune (Guangzhou) Science and Technology Ltd.RecruitingNonsmall Cell Lung Cancer | Solid Tumor, AdultChina
-
Southwest Hospital, ChinaUnknownLymphoma, Large B-Cell, DiffuseChina
-
Wuhan Sian Medical Technology Co., LtdWuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaboratorsUnknownB Cell Lymphoma | Acute Lymphoblastic LeukemiaChina
-
Beijing 302 HospitalLion TCR Pte. Ltd.Recruiting